FDA OKs Sanofi Diabetes Drug In Newly Diagnosed Pediatric Patients

Benzinga_recent_news06-16

The decision expands the therapy's use in pediatric patients and was supported by data from the Phase 3 PROTECT study. The FDA based its decision on results from the PROTECT study, which assessed beta...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2643200981?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=240,format=auto,quality=85/files/images/story/2026/06/15/Sanofi-SA.jpeg","is_english":true,"pubTime":"2026-06-16 01:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643200981","market":"us","top_or_hot":-1,"title":"FDA OKs Sanofi Diabetes Drug In Newly Diagnosed Pediatric Patients","media":"Benzinga_recent_news","content":"<div>\n<p>The decision expands the therapy's use in pediatric patients and was supported by data from the Phase 3 PROTECT study.\nThe FDA based its decision on results from the PROTECT study, which assessed beta...</p>\n\n<a href=\"https://www.benzinga.com/news/fda/26/06/53204769/fda-sanofi-diabetes-drug-in-newly-diagnosed-pediatric-patients\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA OKs Sanofi Diabetes Drug In Newly Diagnosed Pediatric Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA OKs Sanofi Diabetes Drug In Newly Diagnosed Pediatric Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-16 01:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/fda/26/06/53204769/fda-sanofi-diabetes-drug-in-newly-diagnosed-pediatric-patients><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The decision expands the therapy's use in pediatric patients and was supported by data from the Phase 3 PROTECT study.\nThe FDA based its decision on results from the PROTECT study, which assessed beta...</p>\n\n<a href=\"https://www.benzinga.com/news/fda/26/06/53204769/fda-sanofi-diabetes-drug-in-newly-diagnosed-pediatric-patients\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LABU","symbol_name":"三倍做多标普生物-Direxion","start_time":0,"source_url":"https://www.benzinga.com/news/fda/26/06/53204769/fda-sanofi-diabetes-drug-in-newly-diagnosed-pediatric-patients","article_id":"2643200981","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=240,format=auto,quality=85/files/images/story/2026/06/15/Sanofi-SA.jpeg"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/26/06/53204769/fda-sanofi-diabetes-drug-in-newly-diagnosed-pediatric-patients","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2643200981","pubTimestamp":1781543700,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"FDA grants accelerated approval to Sanofi Tzield for children with newly diagnosed stage 3 type 1 diabetes, backed by Phase 3 data.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LABU":"三倍做多标普生物-Direxion","BK4007":"制药","SNYNF":"Sanofi","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"FDA批准赛诺菲糖尿病药物用于新诊断的儿科患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"SNYNF":1.5},"content_text":"The decision expands the therapy's use in pediatric patients and was supported by data from the Phase 3 PROTECT study.\nThe FDA based its decision on results from the PROTECT study, which assessed beta-cell function using C-peptide levels measured during a mixed-meal tolerance test.\nTzield significantly slowed the decline in C-peptide levels versus placebo, with a least-squares mean difference of 0.13 pmol/mL (95% CI: 0.09–0.17; p<0.001) at the end of the study.\nThe agency also reviewed data from more than 900 patients treated with Tzield across its clinical development program. Safety results from PROTECT were consistent with findings from earlier trials.\nThe approval was granted under the FDA's accelerated approval pathway, which allows medicines for serious conditions with unmet medical needs to reach patients based on surrogate endpoints that are reasonably likely to predict clinical benefit.\nContinued approval may depend on verification of clinical benefit in future confirmatory studies.\nTo support that requirement, the Phase 3 BETA-PRESERVE study is currently enrolling participants.\nThe latest approval follows an FDA label expansion in April 2026 that broadened Tzield's use for delaying the onset of stage 3 T1D in patients with stage 2 disease, extending eligibility to children as young as 1 year old.\nTzield is also approved in several international markets.\nSNY Stock Price Activity: Sanofi shares were down 0.97% at $43.82 at the time of publication on Monday, according to Benzinga Pro data.\nImage via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643200981","isCrawlerRequest":true}